

Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting

Mar 10, 2025

Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions

WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting being held March 10-14 in San Diego. During the meeting, the Company's booth will prominently feature its comprehensive hip portfolio, anchored by the new Z1™ Triple-Taper Femoral Hip System, along with the latest technologies for knee and upper extremity reconstruction and key components from its robotic solutions. In addition, Zimmer Biomet is debuting ZBX™, its new Ambulatory Surgery Center (ASC) offering to surgeons and institutions looking to expand their orthopedic footprint.



"I am thrilled to showcase the collective strength and broad range of our musculoskeletal portfolio, including the introduction of several recently cleared technologies, at this year's annual AAOS meeting," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet. "We are in the midst of one of the largest innovation cycles in our company's history. Our broad hip reconstruction portfolio combined with our comprehensive knee portfolio with constructs designed to safeguard against cement and metal sensitivities, our bone-preserving stemless shoulder and now an enhanced suite of ASC solutions, squarely position us at the forefront of delivering customer-centric innovations to improve efficiency and overall patient outcomes."

The highlights at the Zimmer Biomet booth (#3129) include:

Hip Reconstruction Technologies

- **Z1™ Femoral Hip System**, a triple-taper design with expansive innovations within a more comprehensive system, providing more solutions to treat more patients.
- **HAMMR® Automated Hip Impaction System**, designed to address surgeon strain, fatigue and repetitive motion associated with traditional mallet use during bone preparation and device implantation.
- **OrthoGrid Hip AI®**, an AI-powered, fluoroscopy-based technology that provides direct anterior (DA) hip surgeons with intuitive and instantaneous intra-operative tools to assist surgeons in achieving the desired surgical outcomes for component positioning.¹
- **HipInsight™ System**, the first FDA-cleared mixed reality system for hip navigation offers intuitive, intra-operative guidance that leverages the Microsoft HoloLens 2 (mixed reality headset) to help visualize and guide accurate² acetabular component placement and alignment in real-time.

Knee Reconstruction Technologies

- **Persona® Revision SoluTion™ Femur**, a newly cleared revision knee implant component, part of the comprehensive Persona Revision Knee System, offering an alternative to cobalt-chrome (Co-Cr-Mo) alloy for patients with sensitivities to certain metals.
- **Oxford® Cementless Partial Knee**, the only FDA-approved cementless partial knee implant in the U.S. that has been shown to be efficient^{3,4} in the OR, and has been proven to have excellent longevity^{5,6} worldwide.
- **Persona® OsseoTi® Keel Tibia**, a cementless anatomic tibia with a 3D printed porous tray from our clinically proven Persona Knee System⁵⁻⁷ designed to deliver stable initial and biological fixation and intra-operative versatility.⁸
- **Persona IQ® 30 mm Stem**, the world's only smart knee implant, now in a 30 mm stem length, that collects data directly from the knee to provide post-operative recovery insights^{9,10} and trends, allowing care teams to monitor and personalize the total knee arthroplasty patient experience⁹⁻¹¹ with the goal of improving practice efficiency.¹²⁻¹⁵

Upper Extremities Technology

- **OsseoFit™ Stemless Shoulder System**, an anatomically shaped,¹⁶⁻¹⁸ asymmetric stemless shoulder implant designed for stable initial¹⁹⁻²² and biological fixation^{23, 24} by optimizing anatomic humeral fit for stemless shoulder arthroplasty.

ASC Solutions

- **ZBX**, Zimmer Biomet's new comprehensive ASC program offering surgeons an experienced partner to strategically incorporate solutions, unique to each surgeon's needs, providing efficiency in the OR and beyond.

For more information about Zimmer Biomet events at AAOS 2025, visit www.zimmerbiomet.com/academy2025.

Important Safety Information for Oxford Cementless Partial Knee:

The Oxford® Cementless Partial Knee System is indicated for use in unilateral knee procedures with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. It is intended to be implanted without the application of bone cement for patients whose clinical condition would benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee Is not indicated for use in the lateral compartment or for patients with ligament deficiency, or for use in simultaneous bilateral surgery or planned staged bilateral procedures. Potential risks include, but are not limited to, loosening, dislocation, fracture, wear and infection, any of which can require additional surgery. For a full list of product indications, contraindications and warnings, please see the associated product Instructions For Use (IFU).

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.x.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the Company's expectations, plans, intentions, strategies, prospects, business plans, product and service offerings, new product launches, potential

clinical successes, and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

References:

1. Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? *Arthroplasty Today*. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.
2. Dilbone ES, Heimann AF, Leal J, Ryan SP, Wellman SS. Evaluating the Accuracy of a Computed Tomography-Based Mixed-Reality Navigation Tool for Acetabular Component Positioning in Total Hip Arthroplasty. *The Journal of Arthroplasty*. 2025.
3. Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." *JBJS* 95.15 (2013): 1365-1372.
4. Stempin R, Kaczmarek W, Stempin K, Dutka J. Midterm Results of Cementless and Cemented Unicompartmental Knee Arthroplasty with Mobile Meniscal Bearing: A Prospective Cohort Study. *Open Orthop J*. 2017 Oct 31;11:1173-1178. doi: 10.2174/1874325001711011173. PMID: 29290853; PMCID: PMC5721307
5. NJR- UK . The National Joint Registry 21st Annual Report 2024 London, 2024 [Available from: <https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2021st%20Annual%20Report%2024.pdf>]
6. AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report Adelaide, AOA2024 [updated 2024. Available from: <https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0b2282-8fc8-a424-b8d9abb82b1f?t=1727666185313>].
7. American Joint Replacement Registry (AJRR): 2024 Annual Report. Rosemont, IL : American Academy of Orthopaedic Surgeons (AAOS), 2024. <https://www.aaos.org/registries/publications/ajrr-annual-report>

report/#:~:text=When%20citing%20any%20Annual%20Report,at%20RegistryEngagement%40aac
National Joint Registry of England , Wales , Northern Ireland , the Isle of Man and Guernsey . 20th
Annual Report 2023

8. Mueller JK, *et al.* Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en.
November 2022
9. Cushner FD, Yergler J, ElashoffB, Aubin PM, VertaP, Scuderi GR. Staying Ahead of the Curve: The
Case for Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty.
2024;doi:10.1016/j.arth.2024.07.039
10. Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After
Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;2022
11. Cushner FD, Schiller P, Gross J, Mueller JK, Hunter W. A TOTAL KNEE ARTHROPLASTY PROSTHESIS
CAPABLE OF REMOTE PATIENT MONITORING. OrthopaedicProceedings. 2021/06/01 2021;103-
B(SUPP_9):18-18 doi:10.1302/1358-992X.2021.9.018
12. Yocum DS, Redfern RE, Yergler JD. Delayed Recovery Following Total Knee Arthroplasty Identified
by Remote Monitoring With Tibial Extension Sensors. Arthroplasty Today. 2023/10/01/
2023;23:101188. doi: <https://doi.org/10.1016/j.artd.2023.101188>
13. Yocum D, HousholderE, Yergler J. Manipulation under Anesthesia Following TKA with Persona IQ:
A Case Series. J OrthopCase Rep. Aug 2023;13(8):127-131. doi:10.13107/jocr.2023.v13.i08.3844
14. Dundon J, Aubin P, Hunter W. Objective Gait Analysis Following Total Knee Arthroplasty with a
Smart Implant Directs Early Intervention with Manipulation under Anesthesia. Journal of
OrthopaedicExperience & Innovation. 2024;Februarydoi:<https://doi.org/10.60118/001c.89961>.
15. Parikh N, Redfern R, Yocum D, Andel D V, Yergler J. MT46 Patient Experience and Outcomes with
Post-Surgical Remote Monitoring for Patients with Total Knee Arthroplasty (TKA). Value in Health.
2024/06/01/ 2024;27(6, Supplement):S290. doi:<https://doi.org/10.1016/j.jval.2024.03>
16. Mueri, C, Snethen, K, Parisi, R, Son, Yang, Duquin, T Characterization of the Asymmetric Bone
Envelope of the Proximal Humeral Metaphysis for Stemless Shoulder Implants. ORS Orthopaedic
Research Society 2025 Annual Meeting, Paper No. 1175; 2025 Feb 7-11; Phoenix, Arizona .
17. Son, Y, Mueri, C, Snethen, K, Bowman, L, Parisi, R, Duquin, T Optimizing Stemless Humeral
Anchors: Asymmetrical Designs for Minimizing Cortical Bone Impingement while Maximizing
Cancellous Bone Purchase. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No.
2051; 2025 Feb 7-11; Phoenix, Arizona .
18. ZRR_WI_6743_24. Analysis of Potential Cortical Perforation for the OsseoFit Stemless Shoulder.
Zimmer Biomet Internal Research Report on File.
19. Snethen, K, Mueri, C, Kriska, T, Son, Y, Bandi, M The Sensitivity of the Stability of Stemless
Humeral Implants to Surgical, Patient and Design Factors in Reverse Shoulder Arthroplasty.
Presented at the ORS Orthopaedic Research Society Annual Meeting; 2023, Dallas, Texas .

20. Snethen, K, Son, Y, Mueri, C, Bischoff, J The Effect of Press-fit on Initial Stability in Stemless Shoulder Arthroplasty. Presented at the ISTA International Society for Technology in Arthroplasty Annual Meeting; 2022, Maui, Hawaii .
21. Snethen, K, Mueri, C, Son, Y, Parisi, R, Duquin, T The Effect of Geometric Design on Initial Stability of Stemless Shoulder Implants. ORS Orthopaedic Research Society 2025 Annual Meeting, Paper No. 1168; 2025 Feb 7-11; Phoenix, Arizona .
22. ZBTR_30118. Anchor-Level Micromotion of the OsseoFit Stemless Shoulder with Application in Anatomic Total Shoulder Arthroplasty. Zimmer Biomet Internal Design Verification Report on File.
23. Gupta, G Evaluation of Bony Ingrowth Implant Materials in an In Vivo Sheep Long Bone Defect Model 12-04/12-07, February 2013. 32.
24. Gupta, G OsseoTi Porous Metal For Enhanced Bone Integration: an Animal Study. White Paper. 2014. Form No. BMET0718.0-GBL • REV1214.

Laboratory and animal studies are not necessarily indicative of clinical performance.

HipInsight™ System is a trademark of Surgical Planning Associates, Inc.

Microsoft and HoloLens 2 are trademarks of the Microsoft Corporation.

Persona IQ: The objective kinematic data generated by the Canary Canturio® Tibial Extension with CHIRP® System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.

345 E. Main St.

Warsaw, IN 46580

www.zimmerbiomet.com

Media

Heather Zoumas-Lubeski
445-248-0577

heather.zoumaslubeski@zimmerbiomet.com

Kirsten Fallon

781-779-5561

kirsten.fallon@zimmerbiomet.com

Investors

David DeMartino
646-531-6115

david.demartino@zimmerbiomet.com

Zach Weiner

908-591-6955

zach.weiner@zimmerbiomet.com

View original content to download multimedia:<https://www.prnewswire.com/news-releases/zimmer-biomet-highlights-diverse-portfolio-of-orthopedic--musculoskeletal-innovations-at-aaos-2025-annual-meeting-302396091.html>

SOURCE Zimmer Biomet Holdings, Inc.